Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 1Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Ovarian Neoplasms 24Fallopian Tube Neoplasms 13Neoplasms 11Breast Neoplasms 11Triple Negative Breast Neoplasms 5Carcinoma, Ovarian Epithelial 5Solid Tumors 4Sarcoma 4Neoplasm Metastasis 4Sarcoma, Ewing 3Lymphoma 3Carcinoma 3Sarcoma, Kaposi 2Rhabdomyosarcoma 2Recurrence 2Osteosarcoma 2Multiple Myeloma 2Lymphoma, T-Cell 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Advanced Solid Tumors 2AIDS-related Kaposi sarcoma 2Urinary Bladder Neoplasms 1Unrecognized Condition 1Subcutaneous panniculitis-like T-cell lymphoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1

Interventions

Cyclophosphamide 17Dexamethasone 15Bortezomib 14fludarabine phosphate 12Melphalan 12Lenalidomide 10fludarabine 9Filgrastim 8pomalidomide 7Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Rituximab 6Radiotherapy 6Etoposide 6Whole-Body Irradiation 5Cord Blood Stem Cell Transplantation 5Calcium Dobesilate 5Busulfan 5Antilymphocyte Serum 5sargramostim 4Sirolimus 4Panobinostat 4Mycophenolic Acid 4Methylprednisolone 4Cyclosporine 4carfilzomib 3Vorinostat 3Stem Cell Transplantation 3Prednisone 3Methotrexate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms, Plasma Cell × liposomal doxorubicin × Clear all
NCT00744354 2018-01-18

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

UNC Lineberger Comprehensive Cancer Center

Phase 1 Terminated
32 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡